NUVEC a platform technology for the vaccine delivery
Lead Participant:
N4 PHARMA UK LIMITED
Abstract
Nanotechnology platforms, including N4’s propriety NUVEC, are being investigated as vaccine carriers, adjuvants, and drug delivery systems. DNA vaccination indicates great potential for combating a variety of diseases including cancer. Safe and efficient delivery of plasmid DNA to initiate immune responses remains a major barrier in bringing DNA vaccination into human medicine. N4’s NUVEC is a novel platform capable of delivering a range of therapeutic biomolecules whilst simultaneously stimulating the immune system.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| N4 PHARMA UK LIMITED | £169,298 | £ 118,509 |
People |
ORCID iD |
| Nigel Theobald (Project Manager) |